#USA #Fremont #Alamar Biosciences #NULISAseq #Mouse Panel

Alamar Biosciences Unveils the NULISAseq Mouse Panel 120

Alamar Biosciences, a leader in precision proteomics, has proudly announced the launch of its latest innovation, the NULISAseq Mouse Panel 120. This new product aims to revolutionize pre-clinical research and disease detection by providing an extensive range of protein biomarker analysis designed specifically for use in mouse models.

Comprehensive Coverage of Proteins

The NULISAseq Mouse Panel 120 is engineered to identify and analyze 120 different proteins, which are pivotal in understanding critical biological pathways associated with inflammation, neurodegeneration, and immuno-oncology. This comprehensive protein profiling tool is tailored to guide biomedicine researchers, allowing them to explore disease mechanisms and evaluate therapeutic effectiveness more effectively.

Dr. Yuling Luo, Ph.D., founder and CEO of Alamar Biosciences, emphasized the unique functionality of the NULISAseq Mouse Panel. He remarked, “This panel encompasses an unmatched selection of proteins vital for exploring significant biological pathways in pre-clinical models.” Such innovation enables research that is not only significant but also timely in the quest for early disease detection.

Addressing Neurological Research

In a notable feature, the NULISAseq Mouse Panel 120 incorporates a significant focus on neurology, making it the sole multiplex panel with this emphasis. This aspect is especially beneficial for researchers investigating neurodegenerative diseases. Cheryl Wellington, Ph.D., a professor at the University of British Columbia, expressed her enthusiasm about integrating the panel into her research, noting its capacity to enhance understanding of neurophysiology and potentially offer new insights into conditions such as dementia and traumatic brain injuries.

High Sensitivity and Robust Technology

Built upon Alamar’s proprietary multiplex technology, the NULISAseq Mouse Panel 120 showcases exceptional sensitivity and throughput, designed to unveil complex biological interactions. Featuring attomolar sensitivity and a dynamic range of 10 logs, the panel can detect a wide array of proteins, including those present in minute quantities in mouse plasma, such as p-tau217, from as little as 5 µl of sample input.

Researchers armed with the NULISAseq Mouse Panel 120 can engage in deeper explorations of pathophysiological mechanisms and gain crucial perspectives that could lead to groundbreaking therapeutic developments.

Commitment to Advancing Science

Alamar Biosciences is dedicated to empowering scientists in their quest for the earliest disease detection through precision proteomics. With tools like the NULISAseq Panel and the ARGO™ HT System, the company leverages cutting-edge advancements in genomics to provide outstanding protein detection capabilities, well surpassing existing technologies in the market.

For detailed information on the NULISAseq Mouse Panel 120 and to learn more about Alamar's offerings, visit alamarbio.com. Alamar Biosciences remains at the forefront of life sciences, committed to harnessing technology to unlock the secrets behind complex diseases and foster advancements in healthcare.

About Alamar Biosciences
Alamar Biosciences, Inc. is a privately held biotechnology firm focused on precision proteomics. The company’s mission involves harnessing innovative technologies for the early detection of diseases, ensuring that researchers have the necessary tools to achieve the highest standards in their work.